文献速递肝病

Elafibranor治疗UDCA应答不完全的原发性胆汁性胆管炎随机对照试验

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
PubMed 文献 · J Hepatol · 2021-01-21

这项12周双盲II期试验纳入45例UDCA应答不完全的原发性胆汁性胆管炎成人患者,随机接受elafibranor 80mg、120mg或安慰剂。结果显示elafibranor显著降低ALP水平,复合终点达标率高于安慰剂,且瘙痒未加重,药物总体安全耐受。

要点

  • Elafibranor 80mg和120mg均显著降低ALP,安慰剂组ALP升高。
  • 复合终点达标率:80mg组67%、120mg组79%,安慰剂组6.7%。
  • Elafibranor未诱发或加重瘙痒,基线瘙痒患者症状减轻。

核心结论

  • Elafibranor在UDCA应答不完全的PBC患者中总体安全耐受,并显著降低ALP、胆红素与ALP复合终点及其他疾病活动标志物。

研究设计与样本

  • 12周、双盲、安慰剂对照II期试验,纳入45例UDCA应答不完全的PBC成人患者(ALP≥1.67倍正常上限),随机分配至elafibranor 80mg、120mg或安慰剂组,主要终点为12周ALP相对变化(NCT03124108)。

主要发现

  • 12周时ALP相对变化:elafibranor 80mg组-48.3±14.8%(p<0.001 vs 安慰剂),120mg组-40.6±17.4%(p<0.001),安慰剂组+3.2±14.8%。
  • 复合终点(ALP≤1.67倍ULN、ALP下降>15%且总胆红素低于ULN)达标率:80mg组67%、120mg组79%,安慰剂组6.7%。
  • GGT相对变化:80mg组-37.0±25.5%(p<0.001),120mg组-40.0±24.1%(p<0.01),安慰剂组+0.2±26.0%。
  • IgM、5'-核苷酸酶或高敏C反应蛋白等疾病标志物水平同样被elafibranor降低。
  • Elafibranor未诱发或加重瘙痒,基线有瘙痒的患者治疗结束时报告瘙痒症状减轻;所有可能药物相关非严重不良事件均为轻至中度。

临床怎么用

  • 对于UDCA应答不完全的PBC患者,elafibranor可作为潜在二线治疗选择,但需更大规模前瞻性研究确认疗效与安全性。

局限性

  • 本研究为12周II期试验,样本量较小(45例),长期疗效与安全性尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with primary biliary cholangitis (PBC) who have an incomplete response to ursodeoxycholic acid remain at risk of disease progression. We investigated the safety and efficacy of elafibranor, a dual PPARα/δ agonist, in patients with PBC. METHODS: This 12-week, double-blind phase II trial enrolled 45 adults with PBC who had incomplete response to ursodeoxycholic acid (alkaline phosphatase levels ≥1.67-fold the upper limit of normal (ULN). Patients were randomly assigned to elafibranor 80 mg, elafibranor 120 mg or placebo. The primary endpoint was the relative change of ALP at 12 weeks (NCT03124108). RESULTS: At 12 weeks, ALP was reduced by -48.3±14.8% in the elafibranor 80 mg group (p <0.001 vs. placebo) and by -40.6±17.4% in the elafibranor 120 mg group (p <0.001) compared to a +3.2±14.8% increase in the placebo group. The composite endpoint of ALP ≤1.67-fold the ULN, decrease of ALP >15% and total bilirubin below the ULN was achieved in 67% patients in the elafibranor 80 mg group and 79% patients in the elafibranor 120 mg group, vs. 6.7% patients in the placebo group. Levels of gamma-glutamyltransferase decreased by 37.0±25.5% in the elafibranor 80 mg group (p <0.001) and 40.0±24.1% in the elafibranor 120 mg group (p <0.01) compared to no change (+0.2±26.0%) in the placebo group. Levels of disease markers such as IgM, 5'-nucleotidase or high-sensitivity C-reactive protein were likewise reduced by elafibranor. Pruritus was not induced or exacerbated by elafibranor and patients with pruritus at baseline reported less pruritic symptoms at the end of treatment. All possibly drug-related non-serious adverse events were mild to moderate. CONCLUSION: In this randomized phase II trial, elafibranor was generally safe and well tolerated and significantly reduced levels of ALP, composite endpoints of bilirubin and ALP, as well as other markers of disease activity in patients with PBC and an incomplete response to ursodeoxycholic acid. LAY SUMMARY: Patients with primary biliary cholangitis (a rare chronic liver disease) that do not respond to standard therapy remain at risk of disease progression toward cirrhosis and impaired quality of life. Elafibranor is a nuclear receptor agonist that we tested in a randomized clinical trial over 12 weeks. It successfully decreased levels of disease activity markers, including alkaline phosphatase. Thus, this study is the foundation for a larger prospective study that will determine the efficacy and safety of this drug as a second-line therapy. CLINICAL TRIAL REGISTRATION NUMBER: Clinical Trials.gov NCT03124108.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Schattenberg JM, Pares A, Kowdley KV, et al. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol. 2021. PMID: 33484775. doi:10.1016/j.jhep.2021.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。